NASDAQ:ABSI

Absci (ABSI) Stock Forecast, Price & News

$1.38

+0.03 (+2.22%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.29
▼
$1.38
50-Day Range: $1.28
▼
$2.41
52-Week Range: $1.13
▼
$3.71

Volume: 192,923 shs
Average Volume: 527,154 shs
Market Capitalization: $127.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Absci MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 407.2% Upside
$7.00 Price Target
Short Interest: Bearish
3.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.97) to ($0.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

624th out of 970 stocks

Commercial Physical Research Industry

11th out of 14 stocks

3.5

Analyst's Opinion

Consensus Rating
Absci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Absci has a forecasted upside of 407.2% from its current price of $1.38.
Amount of Analyst Coverage
Absci has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.80% of the float of Absci has been sold short.
Short Interest Ratio / Days to Cover
Absci has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Absci has recently increased by 3.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Absci does not currently pay a dividend.
Dividend Growth
Absci does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABSI.

2.5

News and Social Media Coverage

News Sentiment
Absci has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Absci this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Absci insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.58% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 36.30% of the stock of Absci is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Absci are expected to grow in the coming year, from ($0.97) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Absci is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Absci is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Absci has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Absci (NASDAQ:ABSI) Stock

Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ABSI Price History

30 days | 90 days | 365 days | Advanced Chart

ABSI Stock News Headlines

September 21, 2023 | finance.yahoo.com

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

September 20, 2023 | americanbankingnews.com

Absci (NASDAQ:ABSI) Stock Price Up 0.6%

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 12, 2023 | bizjournals.com

Absci lays off 15% of workforce, revises 2023 financial outlook

September 6, 2023 | msn.com

Biotech company Absci lays off 30 employees, about 15% of staff

September 6, 2023 | finance.yahoo.com

Absci to Host R&D Day on October 4, 2023

August 16, 2023 | msn.com

Truist Securities Reiterates Absci (ABSI) Buy Recommendation

August 14, 2023 | finanznachrichten.de

Absci Corporation: Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 14, 2023 | finance.yahoo.com

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

August 14, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 34% in Absci Corporation (NASDAQ:ABSI)

August 10, 2023 | bizjournals.com

Vancouver biotech to develop Bill Gates-funded HIV treatment with Caltech

August 10, 2023 | finance.yahoo.com

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

August 1, 2023 | finance.yahoo.com

Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023

July 27, 2023 | finance.yahoo.com

Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 6, 2023 | msn.com

Absci (ABSI) Price Target Decreased by 16.21% to 6.61

June 15, 2023 | finance.yahoo.com

Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit

June 7, 2023 | finance.yahoo.com

Shareholders in Absci (NASDAQ:ABSI) are in the red if they invested a year ago

June 6, 2023 | finance.yahoo.com

Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

June 4, 2023 | fool.com

Absci (NASDAQ: ABSI)

May 16, 2023 | msn.com

Credit Suisse Reiterates Absci (ABSI) Outperform Recommendation

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Absci (ABSI) Buy Recommendation

May 16, 2023 | finanznachrichten.de

Absci Corporation: Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

May 16, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)

May 15, 2023 | finance.yahoo.com

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

May 15, 2023 | finance.yahoo.com

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

May 12, 2023 | marketwatch.com

University of Oxford's Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

See More Headlines

Receive ABSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter.

ABSI Company Calendar

Last Earnings: 8/14/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABSI
CUSIP: N/A
CIK: 1672688
Web: www.absci.com
Phone: 360-949-1041
Fax: N/A
Employees: 193
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +407.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,900,000.00
Net Margins: -1,305.27%
Pretax Margin: -1,314.54%
Return on Equity: -36.62%
Return on Assets: -31.36%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 5.81
Quick Ratio: 5.81

Sales & Book Value

Annual Sales: $5.75 million
Price / Sales: 22.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.97 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 92,710,000
Free Float: 81,975,000
Market Cap: $127.94 million
Optionable: Not Optionable
Beta: 1.23

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Sean McClain (Age 33)
Founder, CEO, Pres & Director
Comp: $936.2k

Dr. Zachariah Jonasson Ph.D. (Age 50)
Chief Bus. Officer, CFO & Director
Comp: $98.3k

Dr. Sarah Korman J.D. (Age 43)
Ph.D., Chief Legal Officer & Corp. Sec.
Comp: $575.58k

Dr. Andreas Busch Ph.D. (Age 60)
Chief Innovation Officer
Comp: $1.56M

Mr. Todd Bedrick CPA
Sr. VP & Chief Accounting Officer

Mr. Alexander Khan CPA
VP of Fin. & Head of Investor Relations

Mr. Jack Gold
Chief Marketing Officer

Karin Wierinck
Chief People Officer

Melissa Patterson Ph.D.
Chief of Staff

Jens Plassmeier Ph.D.
Sr. VP of Synthetic Biology R&D

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABSI Stock - Frequently Asked Questions

Should I buy or sell Absci stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Absci in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABSI shares.
View ABSI analyst ratings or view top-rated stocks.
What is Absci's stock price forecast for 2023?: 2 Wall Street analysts have issued 12-month target prices for Absci's stock. Their ABSI share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 407.2% from the stock's current price.
View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts.
How have ABSI shares performed in 2023?: Absci's stock was trading at $2.10 at the beginning of 2023. Since then, ABSI shares have decreased by 34.3% and is now trading at $1.38.
View the best growth stocks for 2023 here.
When is Absci's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ABSI earnings forecast.
How were Absci's earnings last quarter?: Absci Co. (NASDAQ:ABSI) announced its earnings results on Monday, August, 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.03. The business had revenue of $3.37 million for the quarter, compared to analyst estimates of $2.59 million. Absci had a negative trailing twelve-month return on equity of 36.62% and a negative net margin of 1,305.27%.
When did Absci IPO?: (ABSI) raised $200 million in an IPO on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share.

What is Absci's stock symbol?: Absci trades on the NASDAQ under the ticker symbol "ABSI."
Who are Absci's major shareholders?: Absci's stock is owned by a number of retail and institutional investors. Top institutional investors include Casdin Capital LLC (1.48%), Platinum Investment Management Ltd. (1.41%), BlackRock Inc. (1.34%), Farther Finance Advisors LLC (0.49%), Geode Capital Management LLC (0.49%) and Renaissance Technologies LLC (0.46%). Insiders that own company stock include Karen K Mcginnis, Sarah Korman, Sean Mcclain and Todd Bedrick.
View institutional ownership trends.
How do I buy shares of Absci?: Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Absci's stock price today?: One share of ABSI stock can currently be purchased for approximately $1.38.
How much money does Absci make?: Absci (NASDAQ:ABSI) has a market capitalization of $127.94 million and generates $5.75 million in revenue each year. The company earns $-104,900,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.
How many employees does Absci have?: The company employs 193 workers across the globe.
How can I contact Absci?: The official website for the company is www.absci.com. The company can be reached via phone at 360-949-1041 or via email at investors@absci.com.

This page (NASDAQ:ABSI) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial